Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longxuejie is a traditional Chinese medicine (TCM) derived from the resin of the *Dracaena cochinchinensis* tree, commonly known as Dragon's Blood. It is primarily utilized for its potent hemostatic, analgesic, and anti-inflammatory properties. Developed and manufactured by companies such as Heilongjiang Success Pharmaceutical Co., Ltd., it is a standard treatment in China for hemorrhoids, where it helps to alleviate swelling, stop bleeding, and promote the healing of anal tissues. The pharmacological activity is attributed to a complex mixture of phenolic compounds, including flavonoids and stilbenes like loureirin A and B, which modulate inflammatory pathways and improve local microcirculation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on longxuejie.